Medical University of South Carolina and Flatiron Health Announce Collaboration
Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.
Flatiron Health has announced a collaboration with the Medical University of South Carolina (MUSC), bringing its oncology support platform to care clinicians at MUSC Hollings Cancer Center, according to a press release.1
Flatiron Assist, Flatiron’s oncology-specific clinical decision support platform, prioritizes evidence-based medicine, site-preferred pathways, and clinical research at the point of care. Through integration with Epic’s electronic health record at MUSC, Flatiron Assist will determine and promote site-preferred pathways and open clinical trials alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care.” said James Hamrick, MD, vice president of clinical oncology at Flatiron Health in the press release. “Flatiron Assist, tailor made for oncology, offers a clinical decision support platform that places emphasis on the latest evidence based medicine, aiming to reduce care variation while increasing access to clinical trials and novel therapies, ensuring patients at MUSC and beyond receive the highest quality of care.”
“MUSC Hollings Cancer Center is excited to partner with Flatiron Health on the development of cancer clinical pathways,” said Craig Lockhart, MD, MHS, director of the division of hematology and oncology and associate director of clinical science at the MUSC Hollings Cancer Center in the press release. “This project will reduce variability in cancer treatment while increasing the quality of cancer care provided across the state of South Carolina.”
Reference
1. The Medical University of South Carolina and Flatiron Health announce collaboration to drive more standardized, efficient, and effective cancer care. News release. March 13, 2024. Accessed March 14, 2024. https://flatiron.com/resources/the-medical-university-of-south-carolina-and-flatiron-health-announce-collaboration-to-drive-more-standardized-efficient-and-effective-cancer-care
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
